HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account
How Local Florida Clinical Trials Are Furthering Research and How to Join Them
How Local Florida Clinical Trials Are Furthering Research and How to Join Them image
Florida Myeloma Community Chapter
event Mar 28, 2023 / 06:30PM - 08:00PM EDT

Event Description

Dr. Dickran Kazandjian joins the Florida Chapter in Myeloma Awareness Month to share why clinical trials are so important, what different types of clinical trials exist, and which ones are openly recruiting in your local area. Come with your questions!

Schedule & Agenda

The panelist Audrey Burton-Bethke
Introductions
6:30 PM
Audrey Burton-Bethke

Audrey introduces the agenda of the event and our featured speaker Dr. Dickran Kazandjian.

person
Member Spotlight
6:35 PM
Audience
The panelist Dickran Kazandjian, MD
Presentation
6:45 PM
Dickran Kazandjian, MD

Dr. Dickran Kazandjian shares why clinical trials are so important, what different types of clinical trials exist, and which ones are openly recruiting in your local area. 

person
Questions and Answers
7:15 PM
Audience

Type your questions in the chat and we will answer them! 

person
Announcements and Post Meeting Mingle
7:25 PM
Audience

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Dickran Kazandjian, MD
Dickran Kazandjian, MD

Dr. Kazandjian’s clinical and translational research interests lie in the treatment of precursor plasma cell disorders including high risk smoldering multiple myeloma and the role of immunotherapy in plasma cell dyscrasias. In addition, he is re-evaluating the role of autologous stem cell transplant (ASCT) in the era of highly efficacious novel-novel drugs, immunotherapy biologics, and cell-based therapies with the hypothesis that certain subsets of patients with myeloma may not benefit by default upfront ASCT.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

+1 800 709 1113

email

Support@healthtree.org

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Abbvie
Genentech
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube